Trial · NCT03763318
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Treatment Emergent Adverse Events | Study Day 85 | Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. |
| Primary | Overall Response Rate | Study Day 29 | Overall Response Rate (ORR) is defined as the number of subjects with a partial response (PR), very good partial response (VGPR), or complete response (CR) who are alive at Day 29. Subjects must not have received new systemic therapy for aGVHD before the Day 29 Visit. |
| Secondary | Time to Maximum EQ001serum Concentration, Tmax | Day 337 | Time to maximum EQ001 serum concentration, Tmax |
| Secondary | Maximum EQ001 Serum Drug Concentration, Cmax | Study Day 337 | Maximum EQ001 serum drug concentration, Cmax |
| Secondary | Minimum EQ001 Serum Drug Concentration, Cmin | Study Day 337 | Minimum EQ001 serum drug concentration prior to next dose, Cmin |
| Secondary | Total EQ001 Exposure Across Time, AUC (From Zero to Infinity) | Study Day 337 | Total EQ001 exposure across time, AUC (from zero to infinity) |
| Secondary | Half Life of EQ001, t1/2 | Study Day 337 | Half life of EQ001, t1/2 |
| Secondary | Volume of Distribution of EQ001, Vd | Study Day 337 | Volume of distribution of EQ001, Vd |
| Secondary | Clearance, Cl | Study Day 337 | Clearance, Cl |
| Secondary | Inflammatory Markers | Study Day 337 | Including but not limited to: IL-1β, IL-2, IL-6, IL-17, IL-21, IL-22, IL-23, IFN-γ, and TGF-β, C-reactive protein |
| Secondary | CD6 Receptor Expression Levels | Study Day 85 | CD6 receptor expression levels - percent of baseline |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03763318/registered